PRESS-RELEASE ·Filed Aug 28, 2026
Press release · FDA
Actionable Insight • Neutral
Monitor Q3 FY27 for IMM-529 partnering progress and Q2 for portfolio expansion.
Latest settled — T+20d ⚠ clustered
IMRN ▲ +0.87% at T+20d
NEUTRAL call +0.87% · α vs SPY +0.61% · entry $1.15 → $1.16
Latest observation: T+39 -11.92% FF3 residual α
T+1d
-3.48%
call -3.48% · α -3.18%
$1.11
settled 8w ago
T+5d
+56.52%
call +56.52% · α +56.41%
$1.80
settled 8w ago
T+20d
+0.87%
call +0.87% · α +0.61%
$1.16
settled 29d ago
T+60d
Pending
in 27d
Price Chart
Loading chart...
Executive Summary
Immuron reported FY26 results with record sales of A$7.7M (+6% YoY) and net profit improvement of A$1.4M. The company highlighted FDA IND approval for IMM-529 (C. diff) and a strategic shift to partner clinical assets.
Key Financial Metrics
Revenue
$7.7M
+6.0% YoY
Key Facts
- FY26 revenue of A$7.7M, up 6% YoY (A$7.3M in FY25)
- Net profit improved by A$1.4M vs FY25 (absolute net profit not stated)
- Cash increased by A$6.2M to A$9.0M, including A$3.0M in term deposits in prior year
- U.S. FDA IND approved for IMM-529 (C. diff) in November 2025
- Strategic decision to partner IMM-124E and IMM-529 for development and commercialization
- Lumanity peak U.S. sales estimates: IMM-124E US$102M, IMM-529 US$400M
Financial Impact
FY26 revenue A$7.7M (+6% YoY); net profit improvement A$1.4M; cash A$9.0M
revenuenet profitcash
Risk Factors
- No absolute net profit figure disclosed; improvement of A$1.4M may still leave the company unprofitable
- Partnering process for IMM-529 and IMM-124E may take longer than expected or fail to materialize
- Canadian sales declined in FY26 despite H2 recovery; U.S. dollar sales growth (+13%) may be offset by FX
- Cash burn reduction is anticipated but not guaranteed; current cash A$9.0M may not fund operations indefinitely
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352589 |
26 reports for IMRN
100% Hit rate @ T+60 Went positive at some point 4 of 4 best @ T+60▲ +29.44%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9200 (−1.08%) |
Oct 23, 2026 3d ago | 6-K | $0.9320 | awaiting T+60 | — | $0.9200 (−1.29%) |
Oct 23, 2026 3d ago | 424B5 | $0.9320 | awaiting T+60 | — | $0.9200 (−1.29%) |
Oct 21, 2026 5d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9200 (−3.06%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9200 (−6.32%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9200 (−11.54%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9200 (−22.69%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9200 (−22.69%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9200 (−26.69%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9200 (−48.89%) |
Showing 10 of 26
US Market Status
Market Closed — Opens in 1h 14m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers